Saved sponsor $48K monthly ($1.8MM total) in management and monitoring fees and increased enrollment timelines by 2 months for Phase III HCV study. How did we do it?

  1. Initially provided CRO oversight for sponsor lacking necessary volume of internal management and oversight resources.
  2. After being tasked with overtaking North America monitoring and management operations, enacted efficiencies to improve study budgeting and timelines.
  3. Transferred study (US, CAN only) from large non-performing CRO to Neozene within 30 days of contract award.
  4. Re-evaluated enrollment delays by closing non-performing sites and incentivizing accruing sites.
  5. Streamlined contract and IRB delays with hospital/university sites by removing third party vendor.
  6. Amended monitoring plan to include risk based monitoring (RBM) criteria and remove costly routine monthly visits.